Accéder au contenu
Merck

SAE2000

SARS-COV-2-Spike-RBD epitope (370-394)

≥95% (HPLC), lyophilized powder

Synonyme(s) :

COVID-19 epitope, Immune response epitope, SARS-COV-2 Spike protein peptide

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement



About This Item

NACRES:
NA.41
UNSPSC Code:
12352203

Nom du produit

SARS-COV-2-Spike-RBD epitope (370-394), ≥95% (HPLC), lyophilized powder

form

lyophilized powder
solid

species reactivity

viral

UniProt accession no.

storage temp.

−20°C

target post-translational modification

unmodified

Quality Level

Gene Information

SARS coronavirus ... S(43740568)

Application

The peptide may be used in various immunochemical techniques including Immunoblotting and Elisa.

Biochem/physiol Actions

SARS-COV-2-Spike-RBD epitope (370-394) is a synthetic peptide corresponding to the amino acid sequence of Spike RBD region (GeneID: QHD43416.1) in positions 370-394.Peptides derived from the SARS-COV-2-Spike-RBD protein can be recognized by anti-SARS-CoV-2-Spike protein antibodies.
The Spike protein (also known as S protein) is a type I trimeric glycoprotein that is presented on the virion membrane, giving it the appearance of a crown. The protein has two subunits: S1, or bulb, that contains the RBD3-10; and S2, or stalk, responsible for the fusion of the virion with the host cell membrane. The main receptor for SARS-CoV and SARS-CoV-2 on the membrane of the target cells is the Angiotensin 2 Converting Enzyme (ACE2), a metallopeptidase present on the membrane of many cells, including type-I and -II pneumocytes, small intestine enterocytes, kidney proximal tubules cells, the endothelial cells of arteries and veins, and the arterial smooth muscle, among other tissues.15-18

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.Data presented is the available current product information and provided as-is. This product has not been tested or verified in any additional applications, sample types, including any clinical use. Experimental conditions must be empirically derived by the user. Our Antibody Guarantee only covers tested applications stated herein and conditions presented in our product information and is not extended to publications.

General description

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or (2019-nCoV) is a novel coronavirus that emerged in December 2019 and since then has infected millions of people worldwide.1 The Spike protein (also known as S protein) is the most studied of the coronaviruses proteins, since it contains the Receptor-Binding-Domain (RBD) for the ligand on the host cell membrane (the ACE2 protein), and also has epitopes recognized by T and B cells

Immunogen

S370-394: nsasfstfkcygvsptklndlcftn

Physical form

Supplied as a lyophilized powder.Purity: ≥95% (HPLC)

Preparation Note

Store the product at −20 °C. After initial thawing, it is recommended to store the peptide in working aliquots at −20°C. Recommended thawing solution: Water.

Classe de stockage

13 - Non Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Mining of epitopes on spike protein of SARS-CoV-2 from COVID-19 patients.
Bao-Zhong Zhang et al.
Cell research, 30(8), 702-704 (2020-07-03)
Chunyan Yi et al.
Cellular & molecular immunology, 17(6), 621-630 (2020-05-18)
Coronavirus disease 2019 (COVID-19), caused by the novel human coronavirus SARS-CoV-2, is currently a major threat to public health worldwide. The viral spike protein binds the host receptor angiotensin-converting enzyme 2 (ACE2) via the receptor-binding domain (RBD), and thus is
Jun Lan et al.
Nature, 581(7807), 215-220 (2020-04-01)
A new and highly pathogenic coronavirus (severe acute respiratory syndrome coronavirus-2, SARS-CoV-2) caused an outbreak in Wuhan city, Hubei province, China, starting from December 2019 that quickly spread nationwide and to other countries around the world1-3. Here, to better understand the
Zhixin Liu et al.
Journal of medical virology, 92(6), 595-601 (2020-02-27)
From the beginning of 2002 and 2012, severe respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) crossed the species barriers to infect humans, causing thousands of infections and hundreds of deaths, respectively. Currently, a novel coronavirus (SARS-CoV-2)
Luis F García
Frontiers in immunology, 11, 1441-1441 (2020-07-03)
The current COVID-19 pandemic began in December 2019 in Wuhan (China) and rapidly extended to become a global sanitary and economic emergency. Its etiological agent is the coronavirus SARS-CoV-2. COVID-19 presents a wide spectrum of clinical manifestations, which ranges from

Contenu apparenté

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique